Cargando…

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy

Acquired generalized lipodystrophy (AGL) is characterized by extensive adipose tissue loss, subsequent development of metabolic disease with severe insulin resistance and hypertriglyceridemia and a varying spectrum of autoimmune or immune-dysregulatory features. We recently evaluated twelve patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavdar, Umit, Akinci, Baris, Foss de Freitas, Maria Cristina, Conjeevaram, Hari, Fox, David, Fontana, Robert, Tayeh, Marwan, Frame, David, Innis, Jeffrey, Walkovich, Kelly, Oral, Elif A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089536/ http://dx.doi.org/10.1210/jendso/bvab048.077

Ejemplares similares

Abnormal Non Esterified Fatty Acid Suppression After a Mixed Meal Test in Patients With Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

FRI055 LYNC-LD: Prospective Multicenter Natural History Study Of Lipodystrophy Syndromes To Determine Prevalence, Incidence And Predictors Of Diabetes And Severe Hypertriglyceridemia, And Their Complications
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

SUN-600 Presence of LMNA p.R582H Pathogenic Variant in Homozygous State Demonstrates Gene Dosage Effect on the Severity of Fat Loss in Lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

RF24 | PSUN126 A Very-Low Calorie Diet Can Reduce Insulin Resistance and Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in a Patient With Familial Partial Lipodystrophy Type 2
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

FRI018 A Novel Truncating Variant Of EBF2 Disrupts Human Adipocyte Differentiation In Lipodystrophy Syndromes: An Example Of A Discovery From A Clinical Translational Pipeline
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

FRI028 Multiple Symmetric Lipomatosis As A Model For Understanding The Importance Of Mitochondria Function On Adipose Tissue Biology
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
por: Ozsu, Elif, et al.
Publicado: (2023)

SAT674 Lipodystrophy: A Hidden Culprit In Uncontrolled Diabetes
por: Sayed, Farah El, et al.
Publicado: (2023)

Leptin Decreases Energy Expenditure but Increases Thyroid Hormone in Patients With Lipodystrophy
por: Quaye, Emmanuel, et al.
Publicado: (2021)

Novel Heterozygous LMNA Variants Causing Familial Partial Lipodystrophy, Dunnigan Variety
por: Wadhwa, Akhilesh, et al.
Publicado: (2021)

FRI054 Partial Lipodystrophy As A Manifestation Of Autoimmune Polyglandular Syndrome 1
por: Agarwal, Shubham, et al.
Publicado: (2023)

Metabolic Improvements After Gastric Sleeve Surgery in a Patient With Familial Partial Lipodystrophy
por: Niaz, Azra, et al.
Publicado: (2021)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

MON-100 Unique miRNA Signature in HIV Lipodystrophy with Reduced Adipose Dicer Expression
por: Srinivasa, Suman, et al.
Publicado: (2019)

SUN-610 Acquired Generalized Lipodystrophy: A Rare Side Effect of PD1-Inhibitor Therapy
por: Shah, Amy, et al.
Publicado: (2020)

RF12 | PSUN80 A Novel DXA Algorithm to Aid in the Diagnosis of Familial Partial Lipodystrophy
por: Harris, Charles, et al.
Publicado: (2022)

SUN-593 Variants in Known Monogenic Causal Genes of Hypertriglyceridemia Are Not Major Contributors for Hypertriglyceridemia in Lipodystrophy Due to a LMNA Mutation
por: Ueda, Masako, et al.
Publicado: (2020)

PSUN100 What Determines Leptin Levels: Moving Beyond Fat Mass
por: Rosenberg, Drake, et al.
Publicado: (2022)

PSUN81 A novel case of congenital generalized lipodystrophy (CGL) with no genetic abnormalites in the AGPAT2, BSCL2, CAV1, and CAVIN1 genes.
por: Mericq, Veronica, et al.
Publicado: (2022)

MON-104 Defining the Contribution of Weight to the Extent of Metabolic Disease in FPLD: Insights from a Retrospective "Matched" Case-Control Study
por: Koo, Eden, et al.
Publicado: (2019)

SAT-110 Long-Term Impact of Gastric Bypass versus Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease: Retrospective Observations from Michigan Bariatric Surgery Cohort
por: Haddad, Raad, et al.
Publicado: (2019)

MON-590 Presence of Diabetes Diminishes the Ultimate Weight Loss After Bariatric Surgery
por: Luo, Yingying, et al.
Publicado: (2020)

ODP008 Nonalcoholic Fatty Liver Disease (NAFLD) Impacts Weight Loss after Bariatric Surgery
por: Abu-Rumaileh, Mohammed, et al.
Publicado: (2022)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
por: Fansa, Sima, et al.
Publicado: (2023)

SUN-112 Arcuate 11-Betahydroxysteroid Dehydrogenase Type1 Regulates Energy Homeostasis
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2019)

Type 2 Diabetes Mellitus Remission in Obese Patients Under Bariatric Surgery: The Role of Preoperative Triglycerides Levels
por: Gonçalves, Vanessa Guerreiro, et al.
Publicado: (2021)

FRI081 Quality Improvement Initiative To Improve Management Of Obesity In A Primary Care Resident Continuity Clinic
por: Fernandez, Maria Gabriela, et al.
Publicado: (2023)

SUN-103 A Direct Comparison Of Metabolic Responses To Nad Repletion In C57bl/6j And C57bl/6n Diet-induced Obesity Mouse Models
por: Garten, Andrea Antje, et al.
Publicado: (2019)

Is Insulin Resistance at Baseline a Predictor of Weight Loss After Bariatric Surgery?
por: Borges-Canha, Marta, et al.
Publicado: (2021)

MON-592 The Impact of Bariatric Surgery on the Risk of Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients
por: Borges-Canha, Marta, et al.
Publicado: (2020)

SAT682 Improving Obesity Counseling Rates In An Academic Internal Medicine Clinic: A Quality Improvement Study
por: Mathew, Anoopa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_791leq9144201ilk792d6cpgti